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N-Acetylglucosaminyltransferase V (GnT-V) is one of the most relevant glycosyltransferases to tumor 
invasion and metastasis. Based on previous findings of molecular recognition between GnT-V and 
synthetic substrates, we designed and synthesized a p-iodophenyl-derivatized trisaccharide, 2-(4-
iodophenyl)ethyl 6-O-[2-O-(2-acetamido-2-deoxy-ß-D-glucopyranosyl)-α-D-mannopyranosyl]-ß-D-




I]1), for use in assays of GnT-
V activity in vitro. The tributyltin derivative, 2-[4-(n-tributylstannyl)phenyl]ethyl 6-O-[2-O-(3,4,6-tri-
O-acetyl-2-acetamido-2-deoxy-ß-D-glucopyranosyl)-3,4,6-tri-O-acetyl-α-D-mannopyranosyl]-2,3,4-tri-
O-acetyl-ß-D-glucopyranoside (21), was synthesized as a precursor for the preparation of [
125
I]1. The 





I]1 was incubated in GnT-V-expressing cells with a UDP-GlcNAc donor, the 
production of β1-6GlcNAc-bearing IPGMG (IPGGMG, 2) was confirmed by radio-HPLC. In kinetic 
analysis, 1 was found to be a good substrate with a Km of 23.7 µM and a Vmax of 159 pmol/h·µg protein. 
[
125









The sugar chains of glycoproteins on cell surfaces, which are constructed by glycosyltransferases and 
glycosidases, change during particular biological events including development, carcinogenesis, and 
malignant transformation. Numerous studies conducted in the last two decades have demonstrated that 
N-acetylglucosaminyltransferase V (GnT-V) is relevant to tumor invasion and metastasis. Since 
Cummings first reported its expression in mouse lymphoma cells in 1982,
1
 GnT-V has been shown to be 
highly expressed in various cancer cell lines and tissues from the early stages of tumorigenesis.
2–8
  In 
addition, studies using GnT-V-deficient mice have directly demonstrated an essential role of GnT-V in 
tumor growth and metastasis.
9,10
   
GnT-V catalyzes the transfer of an N-acetylglucosamine (GlcNAc) residue from a donor, UDP-
GlcNAc, to an acceptor, the mannose α1–6 side chain of the trimannosyl core of N-glycans, to form a 
GlcNAcβ1-6Man linkage. This activity has been assessed predominantly using radiolabeled donors or 
fluorescent-labeled acceptors. In the former case, the production of sugar chains, the non-reducing ends 
of which are modified with radiolabeled GlcNAc by the enzymatic reaction, is measured through the 






  However, there is a problem with 
specificity since UDP-GlcNAc functions as a substrate for many glycosyltransferases. In the latter case, 
a GnT-specific acceptor, GlcNAcβ1-2Manα1-3-(GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAc, 
is labeled with 2-aminopyridine to yield a fluorescent substrate (Gn,Gn-bi-PA). This acceptor is 
obtained from the carbohydrate moiety of human transferrin through laborious and time-consuming 
processes, repeated digestion with various enzymes, chemical modifications, and purification.
13–15
 
Moreover, the PA-oligosaccharide could still be a substrate of GnT-III. 
Thus, we planned and produced a GnT-V-specific radioiodinated substrate for use in assays of GnT-V 
activity in vitro. First, to ensure a high degree of specificity, GlcNAcβ1-2Manα1-6Glc12,16–18 was 
employed as the saccharide moiety on the basis of previous findings; (i) it could not be a substrate of 
GnT-I and GnT-IV because of the lack of an acceptor site for GnT-I and GnT-IV, i.e., a Man residue 
linked to the bisecting Man with an α1–3 linkage, (ii) it is a poor substrate of GnT-III because of the 
 5 
replacement of the acceptor residue, i.e., bisecting Man, with Glc, and (iii) it already carries an GlcNAc 
residue that should be transferred by GnT-II. Second, the 1-hydroxyl of the reducing terminal Glc, 
which was adopted as a substitute of the bisecting Man, was conjugated with a hydrophobic phenethyl 
group without loss of activity.
11,12,16–18
  Finally, the radioiodine 
125
I was considered to be incorporated 
into the para-position of the phenyl ring immediately before the biological assay because the para-
substitution of iodine is effective in preventing deiodination in vivo.
19
 The p-iodophenyl-derivatized 
trisaccharide, 2-(4-iodophenyl)ethyl 6-O-[2-O-(2-acetamido-2-deoxy-ß-D-glucopyranosyl)-α-D-
mannopyranosyl]-ß-D-glucopyranoside, was expected to behave as a substrate for in vitro assays of 
GnT-V activity.  




I]1), and the N-
acetylglucosaminylated product β1-6GlcNAc-bearing IPGMG (IPGGMG, 2). The reaction kinetics of 
[
125
I]1 were evaluated in GnT-V-expressing cells and its recognition by GnT-V was compared with that 
of Gn,Gn-bi-PA. From these results, the usefulness of [
125
I]1 for the GnT-V assay was assessed (Figure 
1). 
 
2. Results and Discussion 
2.1. Chemistry. 
For the synthesis of 1 and [
125
I]1, glycosylation of 3,4,6-tri-O-acetyl-2-O-(3,4,6-tri-O-acetyl-2-
acetamido-2-deoxy-ß-D-glucopyranosyl)-α-D-mannopyranosyl bromide (3) and 2-(4-iodophenyl)ethyl-
2,3,4-tri-O-acetyl-ß-D-glucopyranoside (4) was used as a key reaction (Scheme 1).  
Synthesis of the bromide 3 began with the condensation, which was promoted by silver 
trifluoromethanesulfonate and collidine, of benzyl 3-O-benzyl-4,6-O-benzylidene-α-D-
mannopyranoside (5)
20
 and 3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-ß-D-glucopyranosyl bromide (6)
21
 
to afford disaccharide 7 (57%). Subsequent treatment of 7 with hydrazine hydrate followed by 
acetylation yielded 8 (80%, two steps). Debenzylidenation of 8 in 70% AcOH and subsequent 
acetylation yielded intermediate 9 (80%, two steps), whose hydrogenolysis and acetylation afforded 
 6 
octaacetate 10 (86%, two steps). Subsequent treatment of 10 with 30% HBr-AcOH afforded 3, which 
was used as the glycosyl donor for the next reaction (Scheme 2). 
Synthesis of glycosyl acceptor 4 was achieved by the coupling of 2-(4-bromophenyl)ethyl alcohol and 
2,3,4-tri-O-acetyl-6-O-allyloxycarbonyl--D-glucopyranosyl trichloroacetimidate (13) prepared from 
1,2,3,4-tetra-O-acetyl--D-glucopyranose (11)22 in three steps: protection of the 6-OH group with an 
allyloxycarbonyl group that afforded 12, anomerical deacetylation of 12 with piperidine, and reaction 
with CCl3CN in the presence of DBU that afforded the imidate 13. (Scheme 3).  
Glycosylation of 2-(4-bromophenyl)ethyl alcohol with imidate 13 led to 2-(4-bromophenyl)ethyl 
2,3,4-tri-O-acetyl-6-O-allyloxycarbonyl-ß-D-glucopyranoside (14) (72%), which was subjected to 
palladium-catalyzed deallylation to afford 15 (94%). 15 was reacted with ethyl vinyl ether in the 
presence of a catalytic amount of pyridinium p-toluenesulfonate to form 16 (99%). At this point, 
replacement of the bromo group with an iodo group was investigated before developing the route to 1 
and [
125
I]1. The intermediate, 2-[4-(tributylstannyl)phenyl]ethyl 2,3,4-tri-O-acetyl-6-O-(1-ethoxyethyl)-
ß-D-glucopyranoside (17), was prepared from 16 using a bromo-to-tributyltin exchange reaction 
catalyzed by Pd(0) (47%). The tributyltin derivative 17 was readily converted to 2-(4-iodophenyl)ethyl 
2,3,4-tri-O-acetyl-6-O-(1-ethoxyethyl)-ß-D-glucopyranoside (18) by reaction with iodine (94%). 
Treatment of 17 and 18 with pyridinium p-toluenesulfonate in methanol yielded 19 (95%) and 4 (98%), 
respectively (Scheme 3). 
The treatment of glycosyl donor 3 with glycosyl acceptor 4 in the presence of silver carbonate and 
silver perchlorate in dichloromethane and toluene yielded 20 (67%), which was deacetylated to furnish 
the target compound 1 (59%) (Scheme 4). Next, synthesis of the precursor of [
125
I]1, 22, was attempted 
from which the tributyltin group was expected to be facilely replaced with a radioactive iodo group by 
iododestannylation to yield [
125
I]1. However, deacetylation of 21, which was obtained by the 
condensation of 3 and 19 in the presence of silver perchlorate and collidine (43%), did not yield 22. 
Therefore, the tributyltin derivative 21 was transformed into the fully protected and radiolabeled 
trisaccharide [
125
I]20 by an iododestannylation reaction using hydrogen peroxide as the oxidant. 
 7 
Conventional deacetylation of [
125
I]20 afforded the desired radioiodinated compound [
125
I]1 (Scheme 4). 
It was anticipated that no-carrier-added preparation would result in a final product bearing a theoretical 
specific activity similar to that of 
125
I. The radiochemical identity of [
125
I]1 was verified by co-injection 
with nonradioactive 1 and comparison of their HPLC profiles. The final radioiodinated compound 
[
125
I]1 showed a single peak of radioactivity at the same retention time as that of nonradioactive 1. The 
radioiodinated product was obtained in 50% radiochemical yield with a radiochemical purity of > 95% 
after HPLC. 
Finally, 2-(4-iodophenyl)ethyl 6-O-[2,6-di-O-(2-acetamido-2-deoxy-ß-D-glucopyranosyl)-α-D-
mannopyranosyl]-ß-D-glucopyranoside (IPGGMG, 2), the N-acetylglucosaminylated product of 1, was 
synthesized starting with removal of the benzyliden group of 7 with 70% AcOH to afford 23 (83%). 
Selective silylation of 6-OH of the mannose unit with tert-butyldimethylsilyl chloride yielded 24 (94%), 
the remaining hydroxyl group of which was acetylated to afford 25 (99%). Treatment of 25 with 
pyridinium p-toluenesulfonate afforded 26 (75%), whose glycosylation with the bromide 6 promoted by 
silver trifluoromethanesulfonate and collidine yielded 27 (40%). Removal of the N-phthalimido groups 
with hydrazine hydrate and subsequent acetylation yielded 28 (93%, two steps). Cleavage of the benzyl 
groups of 28 by hydrogenolysis followed by acetylation yielded 29 (72%, two steps). Treatment of 29 in 
acetic anhydride with HBr yielded bromide 30. Glycosylation of 4 with bromide 30 promoted by silver 
carbonate and silver perchlorate yielded 31 (7%, two steps), which was sequentially deacetylated to 
furnish the target compound 2 (Scheme 5). 
 
2.2. Biological Studies. 
A typical HPLC profile of the GnT-V-reaction products of [
125
I]1 is shown in Figure 2. The reaction 
products showed peaks at retention times of 21 and 30 min, respectively, identical to those of the 
nonradioactive compounds 2 and 1. 
This result indicates that GnT-V catalyzes the transfer of a GlcNAc residue from UDP-GlcNAc to 
[
125
I]1 to form a β1-6 linkage, providing evidence that [125I]1 acts as a substrate for GnT-V. 
 8 
The kinetics of the conversion of 1 to 2 by GnT-V were determined using the IPGMG solution 
containing [
125
I]1. This radioiodinated substrate exhibited saturation kinetics at high substrate 
concentrations (Figure 3A). The data satisfied the Michaelis–Menten equation, originally developed for 
enzymatic kinetics. The kinetic parameters were Km = 23.7 µM and Vmax = 159 pmol/h·µg protein, 
determined from the double-reciprocal Lineweaver–Burk plot (Figure 3B). The Km value is one order of 
magnitude lower than that for a fluorescent substrate, Gn,Gn-bi-PA. 
The novel radioiodinated substrate [
125
I]1 was used to assay GnT-V activity in crude extracts of 
various tissues in normal rats. To compare the findings with previous results obtained using Gn,Gn-bi-
PA as a substrate, we assayed the GnT-V activity under similar experimental conditions.
13
  The results 
are summarized in Table 1. This enzyme was uniformly distributed in rat tissues with relatively high 
activity levels in the small intestine and serum. A similar tendency was observed in a previous 
investigation using Gn,Gn-bi-PA.
13
 The reaction velocity using [
125
I]1 was 3- to 22-fold greater than 




We successfully designed and synthesized a novel radioiodinated trisaccharide derivative, [
125
I]1, as a 
synthetic substrate for GnT-V. [
125
I]1 exhibited higher affinity than a fluorescent substrate, Gn,Gn-bi-
PA, suggesting it to be the preferred acceptor for this enzyme. The present findings contribute to the 
development of sensitive in vitro GnT-V assays.  
 
4. Experimental Sections 
4.1. Synthetic Methods 
All reagents were commercial products and used without further purification unless otherwise 
indicated. 
1
H-NMR spectra were obtained on a JEOL JNM EX-270, JNM AL-300, and Varian Unity 
INOVA 400 spectrometer. Signals are given in ppm using tetramethylsilane as an internal standard. MS 
 9 
spectra were determined on a JEOL JMX-SX102A QQ and Shimadzu LCMS-QP8000α mass 
spectrometer. 
4.1.1. Benzyl 3-O-benzyl-4,6-O-benzylidiene-2-O-[3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-ß-D-
glucopyranosyl]-α-D-mannopyranoside (7).  
To a mixture of 5 (255 mg, 0.57 mmol), silver trifluoromethanesulfonate (263 mg, 1.02 mmol), and 
collidine (135 µL, 1.02 mmol) in nitromethane (1 mL) was added a nitromethane (2 mL) solution of 6 
(426 mg, 0.86 mmol) at –20 ºC. The reaction mixture was stirred at –20 ºC for 10 min and room 
temperature for 1.5 h before being filtered through Celite
®
 and concentrated in vacuo. The residue was 
purified by silica gel chromatography (toluene : diethyl ether = 3 : 1) to afford 7 (280 mg, 57%).  
1
H-
NMR (300 MHz, CDCl3) δ: 1.93, 2.08 and 2.09 (each s, 3H), 3.20 (t, J = 10.1 Hz, 1H), 3.52-3.65 (m, 
1H), 3.71-3.76 (m, 1H), 3.88-3.96 (m, 3H), 4.15-4.17 (m, 1H), 4.25 (d of ABd, JAB = 12.2 Hz, J = 2.3 
Hz, 1H), 4.33 (ABd, JAB = 11.7 Hz, 1H), 4.34 (d of ABd, JAB = 12.2 Hz, J = 4.7 Hz, 1H), 4.52 (ABd, JAB 
= 11.7 Hz, 1H), 4.53 (dd, J = 10.8 and 8.4 Hz, 1H), 4.64 (s, 1H), 4.67-4.76 (m, 2H), 5.22 (t, J = 9.6 Hz, 
1H), 5.44 (d, J = 8.4 Hz, 1H), 5.50 (s, 1H), 5.92 (dd, J = 10.7 and 9.1 Hz, 1H), 7.20-7.48 (m, 15H), 
7.77-7.82 (m, 2H), 7.88-7.91 (m, 2H); MS FAB(+) m/z 866 [(M+H)
+
, 26]; HRMS calcd for 
C47H47NO15Na [(M+Na)
+
] 888.2843, found: 888.2845. 
 
4.1.2. Benzyl 3-O-benzyl-4,6-O-benzylidiene-2-O-[3,4,6-tri-O-acetyl-2-acetamido-2-deoxy-ß-D-
glucopyranosyl]-α-D-mannopyranoside (8).  
To an ethanol (50 mL) solution of 7 (900 mg, 1.04 mmol) was added hydrazine·hydrate (80% in water, 
1.5 mL). The reaction mixture was heated at reflux for 4.5 h before being filtered and concentrated in 
vacuo. The residue was purified by silica gel chromatography (chloroform : methanol = 3 : 1) to afford 
the dephthaloyl product (500 mg, 95%). A mixture of the dephthaloyl product (500 mg, 0.82 mmol) and 
acetic anhydride (2.5 mL) in pyridine (5 mL) was stirred overnight at room temperature. The mixture 
was poured into ice water, and extracted with ethyl acetate. The organic layer was washed with water, 
dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel 
 10 
chromatography (chloroform : methanol = 3 : 1) to afford 8 (625 mg, 84%).  
1
H-NMR (400 MHz, 
CDCl3) δ: 1.73, 2.01, 2.02 and 2.02 (each s, 3H) 3.46 (ddd, J = 9.9, 8.3 and 7.6 Hz, 1H), 3.70-3.78 (m, 
1H), 3.82-3.86 (m, 2H), 4.01-4.04 (m, 1H), 4.11-4.24 (m, 5H), 4.49 (ABd, JAB = 11.7 Hz, 1H), 4.70 
(ABd, JAB = 11.4 Hz, 1H), 4.71 (ABd, JAB = 11.7 Hz, 1H), 4.80 (ABd, JAB = 11.4 Hz, 1H), 4.86 (d, J = 
1.6 Hz, 1H), 5.00 (dd, J = 10.1 and 9.3 Hz, 1H), 5.12 (d, J = 8.4 Hz, 1H), 5.52 (d, J = 7.5 Hz, 1H), 5.64 
(s, 1H), 5.67 (dd, J = 10.6 and 9.3 Hz, 1H), 7.27-7.40 (m, 13H), 7.49-7.52 (m, 2H); MS FAB(+) m/z 778 
[(M+H)
+
, 5]; HRMS calcd for C41H48NO14 [(M+H)
+
] 778.3075, found: 778.3070. 
 
4.1.3. Benzyl 4,6-di-O-acetyl-3-O-benzyl-2-O-[3,4,6-tri-O-acetyl-2-acetamido-2-deoxy-ß-D-
glucopyranosyl]-α-D-mannopyranoside (9).  
A solution of 8 (160 mg, 0.21 mmol) and 70% acetic acid (2 mL) was heated to 55 ºC for 6.5 h. The 
mixture was poured into ice water, neutralized with sodium hydrogencarbonate, and extracted with 
chloroform. The organic layer was washed with a saturated sodium hydrogencarbonate solution, dried 
over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel 
chromatography (chloroform : methanol = 10 : 1) to afford the diol compound (125 mg, 91%). A 
mixture of the diol compound (138 mg, 0.20 mmol) and acetic anhydride (0.5 mL) in pyridine (1 mL) 
was stirred overnight at room temperature. The mixture was poured into ice water, neutralized with 
sodium hydrogencarbonate, and extracted with chloroform. The organic layer was washed with water, 
dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel 
chromatography (chloroform : methanol = 20 : 1) to afford 9 (137 mg, 88 %). 
1
H-NMR (400 MHz, 
CDCl3) δ: 1.82 (s, 3H), 2.00 (s, 6H), 2.01, 2.05 and 2.08 (each s, 3H), 3.29 (ddd, J = 9.9, 8.2 and 7.5 Hz, 
1H), 3.71-3.75 (m, 1H), 3.85-3.90 (m, 2H), 4.03 (d of ABd, JAB = 12.1 Hz, J = 2.4 Hz, 1H), 4.10-4.20 
(m, 2H), 4.24 (d of ABd, JAB = 12.1 Hz, J = 6.0 Hz, 1H), 4.49 (ABd, JAB = 11.4 Hz, 1H), 4.51 (ABd, JAB 
= 11.6 Hz, 1H), 4.68 (ABd, JAB = 11.4 Hz, 1H), 4.71 (ABd, JAB = 11.6 Hz, 1H), 4.92 (d, J = 2.0 Hz, 1H), 
4.97 (dd, J = 10.1 and 9.2 Hz, 1H), 5.24 (t, J = 9.6 Hz, 1H), 5.27 (d, J = 8.2 Hz, 1H), 5.57 (d, J = 7.1 Hz, 
 11 
1H), 5.74 (dd, J = 10.5 and 9.2 Hz, 1H), 7.28-7.41 (m, 10H); MS FAB(+) m/z 774 [(M+H)
+
, 9]; HRMS 
calcd for C38H48NO16 [(M+H)
+
] 774.2973, found: 774.2979. 
 
4.1.4. 1,3,4,6-Tetra-O-acetyl-2-O-(3,4,6-tri-O-acetyl-2-acetamido-2-deoxy-ß-D-glucopyrosyl)-D-
mannopyranose (10).  
A mixture of 9 (1.13 g, 1.46 mmol) and Pd-C (10%, ca. 600 mg) in a mixed solvent of ethanol (35 
mL) and acetic acid (12 mL) was stirred overnight at 50 ºC under atmospheric pressure of H2. The 
catalysts were filtered, and the filtrate was evaporated. The residue was chromatographed on a silica gel 
column (chloroform : methanol = 15 : 2) to give the diol compound (740 mg, quant.). A mixture of the 
diol compound (225 mg, 0.38 mmol) and acetic anhydride (2 mL) in pyridine (4 mL) was stirred 
overnight at room temperature. The solvent was removed, and the residue was purified by silica gel 
chromatography (chloroform : methanol = 10 : 1) to give 10 (257 mg, 86 %). 
1
H-NMR (400 MHz, 
CDCl3) δ: 1.96, 2.01, 2.02, 2.04, 2.05, 2.08, 2.12 and 2.15 (each s, 3H), 3.28 (ddd, J = 7.1, 5.0 and 2.2 
Hz, 1H), 3.87 (ddd, J = 10.6, 8.6 and 8.4 Hz, 1H), 3.96 (ddd, J = 7.3, 4.9 and 2.4 Hz, 1H), 4.02 (d of 
ABd, JAB = 12.3 Hz, J = 2.2 Hz, 1H), 4.07 (d of ABd, JAB = 12.5 Hz, J = 2.4 Hz, 1H), 4.20 (dd, J = 3.3 
and 2.4 Hz, 1H), 4.22 (d of ABd, JAB = 12.5 Hz, J = 5.0 Hz, 1H), 4.25 (d of ABd, JAB = 12.3 Hz, J = 5.0 
Hz, 1H), 4.80 (d, J = 8.4 Hz, 1H), 5.04 (dd, J = 10.3 and 3.8 Hz, 1H), 5.06 (dd, J = 10.1 and 1.8 Hz, 1H), 
5.33 (dd, J = 10.8 and 4.2 Hz, 1H), 5.36 (dd, J = 10.8 and 4.0 Hz, 1H), 5.79 (d, J = 8.6 Hz, 1H), 5.98 (d, 
J = 2.0 Hz, 1H); MS FAB(+) m/z 678 [(M+H)
+






mannopyranosyl bromide (3).  
To a solution of 10 (136 mg, 0.20 mmol) and acetic anhydride (1.5 mL) was added hydrogen bromide 
(30% in acetic acid, 3 mL). The reaction mixture was stirred at room temperature for 4 h under a 
nitrogen atmosphere, and hydrogen bromide (30% in acetic acid, 3 mL) was added. The mixture was 
 12 
stirred overnight at room temperature, poured into ice water, and extracted with chloroform. The 
organic layer was washed with water and a saturated sodium hydrogencarbonate solution, dried over 
sodium sulfate, filtered, and evaporated to give 3 (137 mg, quant.). 
1
H-NMR (400 MHz, CDCl3) δ: 1.95, 
2.02, 2.03, 2.05, 2.08, 2.09 and 2.11 (each s, 3H), 3.60 (dt, J = 10.8 and 8.2 Hz, 1H), 3.71-3.77 (m, 1H), 
4.00-4.03 (m, 1H), 4.08-4.14 (m, 2H), 4.24-4.28 (m, 2H), 4.48 (dd, J = 3.3 and 1.7 Hz, 1H), 5.01 (dd, J 
= 9.9 and 9.3 Hz, 1H), 5.08 (d, J = 8.2 Hz, 1H), 5.35-5.52 (m, 3H), 5.87 (d, J = 7.9 Hz, 1H), 6.29 (d, J = 
1.3 Hz, 1H); MS FAB(+) m/z 698 (M
+
, 7); HRMS calcd for C26H36BrNO16 (M
+
) 698.1296, found: 
698.1301. 
 
4.1.6. 1,2,3,4-Tetra-O-acetyl-6-O-allyloxycarbonyl--D-glucopyranose (12).  
To a tetrahydrofuran (30 mL) solution of 1,2,3,4-tetra-O-acetyl--D-glucopyranose (11) (1.38 g, 4.31 
mmol) in an ice bath were added allyl chloroformate (1.37 mL, 12.9 mmol) and pyridine (1.39 mL, 17.2 
mmol). The reaction mixture was stirred at room temperature for 2 h under a nitrogen atmosphere, 
poured into aqueous ammonium chloride (15 mL), and extracted with ethyl acetate. The organic layer 
was washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was 
purified by silica gel chromatography (hexane : ethyl acetate = 2 : 1) to afford 12 (1.63 g, 87%).  
1
H-
NMR (300 MHz, CDCl3) δ: 2.01, 2.03, 2.04 and 2.10 (each s, 3H), 3.84 (m, 1H), 4.22-4.32 (m, 2H), 
4.61-4.63 (m, 2H), 5.06-5.16 (m, 2H), 5.23-5.39 (m, 3H), 5.74 (d, J = 7.7 Hz, 1H), 5.86-5.99 (m, 1H); 
MS FAB(+) m/z 455 [(M+Na)
+
, 100]; HRMS calcd for C18H24O12Na [(M+Na)
+
] 455.1166, found: 
455.1171. 
 
4.1.7. 2,3,4-Tri-O-acetyl-6-O-allyloxycarbonyl--D-glucopyranosyl trichloroacetimidate (13).  
To a tetrahydrofuran (50 mL) solution of 12 (3.45 g, 11.4 mmol) was added piperidine (2.26 mL, 22.8 
mmol). The reaction mixture was stirred at room temperature for 20 h under a nitrogen atmosphere. 
After the reaction was completed, the mixture was diluted with ethyl acetate. The organic layer was 
washed with 10% hydrochloric acid and brine, dried over sodium sulfate, filtered, and concentrated in 
 13 
vacuo. The residue was purified by silica gel chromatography (hexane : ethyl acetate = 2 : 1) to give a 
crude compound (2.41 g). To a solution of the crude compound (2.41 g) in dichloromethane (30 mL) 
were added trichloroacetonitrile (1.23 mL, 12.3 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (46 µl, 
0.31 mmol). The reaction mixture was stirred at room temperature for 2 h. The solvent was removed, 
and the residue was purified by silica gel chromatography (hexane : ethyl acetate = 3 : 1) to afford 13 
(2.73 g, 64 %, 2 steps). 
1
H-NMR (300 MHz, CDCl3) δ: 2.01, 2.04 and 2.06 (each s, 3H), 4.22-4.33 (m, 
3H), 4.62 (dt, J = 1.3 and 5.9 Hz, 2H), 5.12 (dd, J = 3.7 and 10.2 Hz, 1H), 5.19 (t, J = 9.6 Hz, 1H), 5.28 
(qd, J = 1.3 and 10.5 Hz, 1H), 5.36 (qd, J = 1.5 and 17.2 Hz, 1H), 5.58 (t, J = 9.6 Hz, 1H), 5.92 (ddt, J = 
5.9, 10.5 and 17.2 Hz, 1H), 6.57 (d, J = 3.7 Hz, 1H), 8.69 (s, 1H); MS FAB(+) m/z 556 [(M+Na)
+
, 11]; 
HRMS calcd for C18H22O11Cl3NNa [(M+Na)
+
] 556.0156, found: 556.0152. 
 
4.1.8. 2-(4-Bromophenyl)ethyl 2,3,4-tri-O-acetyl-6-O-allyloxycarbonyl-ß-D-glucopyranoside (14).  
To a dichloromethane (20 mL) solution of 13 (904 mg, 1.69 mmol) and 2-(4-bromophenyl)ethyl 
alcohol (197 µL, 1.41 mmol) was added boron trifluoride diethyl etherate (36 µL, 0.28 mmol). The 
reaction mixture was stirred at –20 ºC for 2 h, and a saturated sodium hydrogencarbonate solution was 
added. Following extraction with chloroform, the organic phase was dried over sodium sulfate and 
filtered. The solvent was removed, and the residue was purified by silica gel chromatography (toluene : 
diethyl ether = 3 : 1) to afford 14 (584 mg, 72%).  
1
H-NMR (270 MHz, CDCl3) δ: 1.89, 1.99 and 2.03 
(each s, 3H), 2.80-2.86 (m, 2H), 3.58-3.75 (m, 2H), 4.06-4.29 (m, 3H), 4.46 (d, J = 7.9 Hz, 1H), 4.62 (dt, 
J = 1.3 and 5.9 Hz, 2H), 4.93-5.05 (m, 2H), 5.14-5.40 (m, 3H), 5.85-5.99 (m, 1H), 7.04-7.08 (m, 2H), 
7.37-7.40 (m, 2H); MS FAB(+) m/z 595 [(M+Na)
+
, 54]; HRMS calcd for C24H29O11BrNa [(M+Na)
+
] 
595.0791, found: 595.0787. 
 
4.1.9. 2-(4-Bromophenyl)ethyl 2,3,4-tri-O-acetyl-ß-D-glucopyranoside (15).  
To a tetrahydrofuran (30 mL) solution of 14 (2.12 g, 3.70 mmol) were added 
tetrakis(triphenylphosphine)palladium (0) (214 mg, 0.18 mmol), triphenylphosphine (291 mg, 1.11 
 14 
mmol), and formic acid (279 mL, 7.39 mmol). The reaction mixture was stirred at room temperature for 
6 h under a nitrogen atmosphere. After the reaction was completed, the mixture was diluted with ethyl 
acetate. The organic layer was washed with water and brine, dried over sodium sulfate, filtered, and 
concentrated in vacuo. The residue was purified by silica gel chromatography (hexane : ethyl acetate = 
1 : 1) to afford 15 (1.70 g, 94%). 
1
H-NMR (300 MHz, CDCl3) δ: 1.89, 2.00 and 2.05 (each s, 3H), 2.81-
2.86 (m, 2H), 3.46-3.52 (m, 2H), 3.55-3.67 (m, 3H), 3.71-3.75 (m, 1H), 4.13 (ddd, J = 9.5, 6.1 and 5.9 
Hz, 1H), 4.49 (d, J = 7.9 Hz, 1H), 4.96 (dd, J = 9.7 and 7.9 Hz, 1H), 5.01 (dd, J = 9.7 and 9.5 Hz, 1H), 
5.21 (t, J = 9.5 Hz, 1H), 7.05-7.08 (m, 2H), 7.38-7.41 (m, 2H); MS FAB(+) m/z 511 [(M+Na)
+
, 99]; 
HRMS calcd for C20H25O9BrNa [(M+Na)
+
] 511.0580, found: 511.0573. 
 
4.1.10. 2-(4-Bromophenyl)ethyl 2,3,4-tri-O-acetyl-6-O-(1-ethoxyethyl)-ß-D-glucopyranoside (16).  
To a dichloromethane (3 mL) solution of 15 (173 mg, 0.35 mmol) were added ethyl vinyl ether (51 
µL, 0.53 mmol), and pyridinium p-toluenesulfonate (9 mg, 0.035 mmol). The reaction mixture was 
stirred at room temperature for 1 h under a nitrogen atmosphere. The solvent was removed, and the 
residue was purified by silica gel chromatography (hexane : ethyl acetate = 2 : 1) to afford 16 (197 mg, 
99%). 
1
H-NMR (300 MHz, CDCl3) δ: 1.17 (t, J = 7.1 Hz, 1.5H), 1.18 (t, J = 7.1 Hz, 1.5H), 1.28 (d, J = 
5.3 Hz, 1.5H), 1.29 (d, J = 5.3 Hz, 1.5H), 1.89 (s, 1.5H), 1.89 (s, 1.5H), 1.99 (s, 3H), 2.02 (s, 3H), 2.80-
2.85 (m, 2H), 3.40-3.70 (m, 6H), 4.06-4.16 (m, 1H), 4.46 (d, J = 7.9 Hz, 1H), 4.70 (q, J = 5.3 Hz, 0.5H), 
4.72 (q, J = 5.3 Hz, 0.5H), 4.96 (dd, J = 9.7 and 7.9 Hz, 1H), 5.03 (dd, J = 9.7 and 9.5 Hz, 1H), 5.16 (t, 
J = 9.5 Hz, 1H), 7.05-7.07 (m, 2H), 7.37-7.40 (m, 2H); MS FAB(+) m/z 583 [(M+Na)
+
, 34]; HRMS 
calcd for C24H33O10BrNa [(M+Na)
+
] 583.1155, found: 583.1151. 
 
4.1.11. 2-[4-(Tributylstannyl)phenyl]ethyl 2,3,4-tri-O-acetyl-6-O-(1-ethoxyethyl)-ß-D-
glucopyranoside (17).  
To a N,N-dimethylformamide (5 mL) solution of 16 (161 mg, 0.29 mmol) were added 
tetrakis(triphenylphosphine)palladium (0) (33 mg, 0.029 mmol), triphenylphosphine (15 mg, 0.057 
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mmol), and bis(tributyltin) (289 µL, 0.57 mmol). The reaction mixture was stirred at 100 ºC for 4 h 
under a nitrogen atmosphere. The solvent was removed, and the residue was purified by silica gel 
chromatography (hexane : ethyl acetate = 5 : 1 to 2 : 1) to afford 17 (103 mg, 47%). 
1
H-NMR (300 MHz, 
CDCl3) δ: 0.88 (t, J = 7.3 Hz, 9H), 1.02 (t, J = 8.1 Hz, 6H), 1.17 (t, J = 7.2 Hz, 1.5H), 1.18 (t, J = 7.2 Hz, 
1.5H), 1.27-1.36 (m, 9H), 1.47-1.57 (m, 6H), 1.89 (s, 3H), 1.99 (s, 3H), 2.02 (s, 3H), 2.86 (t, J = 6.8 Hz, 
2H), 3.43-3.71 (m, 6H), 4.08-4.15 (m, 1H), 4.48 (d, J = 8.1 Hz, 1H), 4.70-4.72 (m, 1H), 4.98 (t, J = 8.1 
Hz, 1H), 5.04 (t, J = 9.5 Hz, 1H), 5.17 (t, J = 9.5 Hz, 1H), 7.13-7.16 (m, 2H), 7.35-7.37 (m, 2H); MS 
FAB(+) m/z 795 [(M+Na)
+
, 43]; HRMS calcd for C36H60O10SnNa [(M+Na)
+
] 795.3106, found: 
795.3111. 
 
4.1.12. 2-(4-Iodophenyl)ethyl 2,3,4-tri-O-acetyl-6-O-(1-ethoxyethyl)-ß-D-glucopyranoside (18).  
To a dichloromethane (10 mL) solution of 17 (305 mg, 0.40 mmol) was added iodine (201 mg, 0.79 
mmol). The reaction mixture was stirred at 0 ºC for 2 h under a nitrogen atmosphere, and a saturated 
sodium hydrogencarbonate and sodium thiosulfate solution was added. Following extraction with 
chloroform, the organic phase was dried over sodium sulfate and filtered. The solvent was removed, and 
the residue was purified by silica gel chromatography (toluene : diethyl ether = 3 : 1) to afford 18 (226 
mg, 94%). 
1
H-NMR (300 MHz, CDCl3) δ: 1.17 (t, J = 7.0 Hz, 1.5H), 1.17 (t, J = 7.0 Hz, 1.5H), 1.27 (d, 
J = 5.5 Hz, 1.5H), 1.29 (d, J = 5.1 Hz, 1.5H), 1.89 (s, 3H), 1.99 (s, 3H), 2.01 (s, 3H), 2.79-2.84 (m, 2H), 
3.42-3.69 (m, 6H), 4.10 (dt, J = 9.5 and 5.9 Hz, 1H), 4.45 (d, J = 7.7 Hz, 1H), 4.70 (q, J = 5.1Hz, 0.5H), 
4.71 (q, J = 5.1 Hz, 0.5H), 4.95 (dd, J = 9.7 and 7.7 Hz, 1H), 5.03 (dd, J = 9.7 and 9.5 Hz, 1H), 5.16 (t, 
J = 9.5 Hz, 1H), 6.92-6.95 (m, 2H), 7.57-7.59 (m, 2H); MS FAB(+) m/z 631 [(M+Na)
+
, 16]; HRMS 
calcd for C24H33O10INa [(M+Na)
+
] 631.1016, found: 631.1011. 
 
4.1.13. 2-[4-(Tributylstannyl)phenyl]ethyl 2,3,4-tri-O-acetyl-ß-D-glucopyranoside (19).  
A mixture of 17 (310 mg, 0.40 mmol), pyridinium p-toluenesulfonate (10 mg, 0.040 mmol), and 
methanol (10 mL) was stirred at room temperature for 2 h. The solvent was removed, and the residue 
 16 
was purified by silica gel chromatography (hexane : ethyl acetate = 3 : 1 to 2 : 1) to afford 19 (268 mg, 
95%). 
1
H-NMR (300 MHz, CDCl3) δ: 0.88 (t, J = 7.2 Hz, 9H), 1.02 (t, J = 8.1 Hz, 6H), 1.33 (sextet, J = 
7.2 Hz, 6H), 1.53 (tt, J = 8.1 and 7.2 Hz, 6H), 1.89 (s, 3H), 2.00 (s, 3H), 2.04 (s, 3H), 2.12 (t, J = 6.1 Hz, 
1H), 2.86 (dd, J = 7.2 and 6.6 Hz, 2H), 3.46-3.52 (m, 1H), 3.55-3.61 (m, 1H), 3.63-3.76 (m, 2H), 4.13 
(dt, J = 9.5 and 6.1 Hz, 1H), 4.53 (d, J = 8.1 Hz, 1H), 4.98 (dd, J = 9.7 and 8.1 Hz, 1H), 5.02 (dd, J = 
9.7 and 9.5 Hz, 1H), 5.22 (t, J = 9.5 Hz, 1H), 7.14-7.16 (m, 2H), 7.35-7.38 (m, 2H); MS FAB(+) m/z 
723 [(M+Na)
+
, 100]; HRMS calcd for C32H52O9NaSn [(M+Na)
+
] 723.2531, found: 723.2533. 
 
4.1.14. 2-(4-Iodophenyl)ethyl 2,3,4-tri-O-acetyl-ß-D-glucopyranoside (4).  
To a methanol (10 mL) solution of 18 (222 mg, 0.41 mmol) was added pyridinium p-toluenesulfonate 
(10 mg, 0.036 mmol). The reaction mixture was stirred at 55 ºC for 2 h. The solvent was removed, and 
the residue was purified by silica gel chromatography (hexane : ethyl acetate = 1 : 1) to afford 4 (192 
mg, 98%). 
1
H-NMR (300 MHz, CDCl3) δ: 1.89, 2.00 and 2.05 (each s, 3H), 2.20 (br.t, J = Hz, 1H), 
2.80-2.84 (m, 2H), 3.46-3.52 (m, 1H), 3.55-3.77 (m, 3H), 4.12 (dt, J = 9.5 and 5.9 Hz, 1H), 4.49 (d, J = 
7.7 Hz, 1H), 4.96 (dd, J = 9.5 and 7.7 Hz, 1H), 5.01 (t, J = 9.5 Hz, 1H), 5.21 (t, J = 9.5 Hz, 1H), 6.93-
6.95 (m, 2H), 7.58-7.60 (m, 2H); MS FAB(+) m/z 559 [(M+Na)
+
, 100]; HRMS calcd for C20H25O9NaI 
[(M+Na)
+





To a solution of 4 (214 mg, 0.40 mmol), dichloromethane (10 mL), and toluene (10 mL) was added 
silver carbonate (121 mg, 0.44 mmol). The reaction mixture was stirred at room temperature for 1 h 
under a nitrogen atmosphere, and silver perchlorate (12 mg, 0.060 mmol) was added. After stirring for 
20 min at room temperature, a solution of 3 (334 mg, 0.48 mmol), dichloromethane (10 mL), and 
toluene (10 mL) was added and the mixture was stirred for another 15 h. After the reaction was 
 17 
completed, the mixture was filtered. The filtrate was concentrated in vacuo, and the residue was purified 
by silica gel chromatography (hexane : ethyl acetate = 4 : 1 to ethyl acetate only) to afford 20 (310 mg, 
67%). 
1
H-NMR (300 MHz, CDCl3) δ: 1.87, 1.93, 1.94, 2.00, 2.01, 2.01, 2.03, 2.05, 2.09 and 2.09 (each 
s, 3H), 2.82-2.88 (m, 2H), 3.36-3.45 (m, 1H), 3.51-3.54 (m, 1H), 3.61-3.78 (m, 4H), 3.87-3.92 (m, 1H), 
4.00-4.09 (m, 2H), 4.13-4.20 (m, 3H), 4.26-4.32 (m, 1H), 4.47 (d, J = 7.7 Hz, 1H), 4.70 (s, 1H), 4.89-
5.05 (m, 4H), 5.08 (d, J = 8.1 Hz, 1H), 5.18 (t, J = 9.5 Hz, 1H), 5.21 (t, J = 9.9 Hz, 1H), 5.60 (t, J = 9.2 
Hz, 1H), 5.61 (d, J = 9.2 Hz, 1H), 6.94-6.97 (m, 2H), 7.56-7.59 (m, 2H); MS FAB(+) m/z 1154 [(M+H)
+
, 
3]; HRMS calcd for C46H61O25NI [(M+H)
+





To a solution of 19 (30 mg, 0.043 mmol), dichloromethane (1 mL), and toluene (1 mL) was added 
collidine (14 µL, 0.10 mmol). The reaction mixture was stirred at room temperature for 20 min under a 
nitrogen atmosphere, and silver perchlorate (11 mg, 0.052 mmol) was added. After stirring for 20 min at 
room temperature, a solution of 3 (36 mg, 0.052 mmol), dichloromethane (2 mL), and toluene (2 mL) 
was added and the mixture was stirred for another 5 h. After the reaction was completed, the mixture 
was filtered. The filtrate was washed with 1% hydrochloric acid, dried over sodium sulfate, filtered, and 
concentrated in vacuo. The residue was purified by silica gel chromatography (ethyl acetate) to afford 
21 (24 mg, 43%). 
1
H-NMR (300 MHz, CDCl3) δ: 0.88 (t, J = 7.3 Hz, 9H), 1.01 (t, J = 8.2 Hz, 6H), 1.32 
(sextet, J = 7.3 Hz, 6H), 1.52 (tt, J = 8.2 and 7.3 Hz, 6H), 1.85 (s, 3H), 1.90 (s, 3H), 1.93 (s, 3H), 2.00 (s, 
3H), 2.00 (s, 3H), 2.01 (s, 3H), 2.03 (s, 3H), 2.05 (s, 3H), 2.09 (s, 3H), 2.09 (s, 3H), 2.85-2.91 (m, 2H), 
3.38-3.48 (m, 1H), 3.52-3.55 (m, 1H), 3.66-3.80 (m, 4H), 3.90-3.95 (m, 1H), 4.00-4.04 (m, 2H), 4.13-
4.21 (m, 3H), 4.26-4.32 (m, 1H), 4.49 (d, J = 7.9 Hz, 1H), 4.69 (s, 1H), 4.91-5.07 (m, 5H), 5.16-5.25 (m, 
2H), 5.51-5.62 (m, 2H), 7.13-7.16 (m, 2H), 7.33-7.36 (m, 2H); MS FAB(+) m/z 1318 [(M+H)
+
, 18]; 
HRMS calcd for C58H88O25NSn [(M+H)
+




mannopyranosyl]-ß-D-glucopyranoside (1).  
To a methanol (10 mL) solution of 20 (188 mg, 0.16 mmol) was added sodium methoxide (28% in 
methanol, 332 µL, 1.63 mmol) and the mixture was stirred at room temperature for 2 h. After the 
reaction was completed, the mixture was neutralized with Amberlyst
®
 15 (ca. 1.0 g) and filtered. The 
filtrate was concentrated in vacuo and the residue was purified by a recycle HPLC (LC-908, Japan 
Analytical Industry Co. Ltd. Tokyo, Japan) on a reversed phase column (methanol : distilled water = 7 : 
3) to afford 1 (74 mg, 59%). 
1
H-NMR (300 MHz, CD3OD) δ: 1.99 (s, 3H), 2.89-2.92 (m, 2H), 3.16-4.04 
(m, 21H), 4.28 (d, J = 7.3 Hz, 1H), 4.46 (d, J = 7.7 Hz,1H), 7.06-7.09 (m, 2H), 7.59-7.62 (m, 2H); MS 
FAB(+) m/z 776 [(M+H)
+
, 10]; HRMS calcd for C28H43O16NI [(M+H)
+
] 776.1627, found: 776.1635. 
 
4.1.18. Benzyl 3-O-benzyl-2-O-[3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-ß-D-glucopyranosyl]-α-D-
mannopyranoside (23).  
A mixture of 7 (1.45 g, 1.67 mmol) and 70% acetic acid (10 mL) was stirred at 55 ºC for 2 h. The 
mixture was poured into ice water, neutralized with sodium hydrogencarbonate, and extracted with 
chloroform. The organic layer was washed with a saturated sodium hydrogencarbonate solution, dried 
over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel 
chromatography (chloroform : methanol = 20 : 1) to afford 23 (1.07 g, 83%). 
1
H-NMR (300 MHz, 
CDCl3) δ: 1.26 (br.t, J = 6.6 Hz, 1H), 1.89 (s, 3H), 2.01 (s, 3H), 2.04 (s, 3H), 2.28 (br.s, 1H), 3.12-3.16 
(m, 1H), 3.37-3.46 (m, 2H), 3.68-3.69 (m, 2H), 3.84-3.90 (m, 1H), 4.13 (br.s, 1H), 4.20 (d of ABd, JAB = 
12.4 Hz, J = 2.4 Hz, 1H), 4.27 (d of ABd, JAB = 12.4 Hz, J = 4.8 Hz, 1H), 4.30 (ABd, JAB = 11.7 Hz, 
1H), 4.38 (ABd, JAB = 11.0 Hz, 1H), 4.41 (dd, J = 10.6 and 8.4 Hz, 1H), 4.49 (ABd, JAB = 11.7 Hz, 1H), 
4.62 (d, J = 1.5 Hz, 1H), 4.75 (ABd, JAB = 11.0 Hz, 1H), 5.17 (t, J = 9.5 Hz, 1H), 5.36 (d, J = 8.4 Hz, 
1H), 5.87 (dd, J = 11.0 and 9.2 Hz, 1H), 7.18-7.21 (m, 2H), 7.28-7.34 (m, 8H), 7.76-7.80 (m, 2H), 7.85-
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7.88 (m, 2H); MS FAB(+) m/z 800 [(M+Na)
+
, 53]; HRMS calcd for C40H43O15NNa [(M+Na)
+
] 
800.2530, found: 800.2527. 
 
4.1.19. Benzyl 3-O-benzyl-6-O-tert-butyldimethylsilyl-2-O-[3,4,6-tri-O-acetyl-2-deoxy-2-
phthalimido-ß-D-glucopyranosyl]-α-D-mannopyranoside (24).  
To a N,N-dimethylformamide (10 mL) solution of 23 (1.07 g, 1.38 mmol) were added tert-
butyldimethylsilyl chloride (311 mg, 2.06 mmol) and imidazole (281 mg, 4.13 mmol). The reaction 
mixture was stirred at room temperature for 16 h under a nitrogen atmosphere, poured into aqueous 
ammonium chloride (20 mL), and extracted with ethyl acetate. The organic layer was washed with 
water, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica 
gel chromatography (hexane : ethyl acetate = 2 : 1) to afford 24 (1.15 g, 94%).  
1
H-NMR (300 MHz, 
CDCl3) δ: -0.13 (s, 3H), -0.12 (s, 3H), 0.78 (s, 9H), 1.86 (s, 3H), 2.00 (s, 3H), 2.03 (s, 3H), 2.64 (br.s, 
1H), 3.14-3.20 (m, 1H), 3.41-3.49 (m, 2H), 3.60-3.71 (m, 2H), 3.82-3.87 (m, 1H), 4.13-4.26 (m, 3H), 
4.31 (ABd, JAB = 11.4 Hz, 1H), 4.40 (d, J = 9.5 Hz, 1H), 4.45 (ABd, JAB = 11.2 Hz, 1H), 4.56 (ABd, JAB 
= 11.4 Hz, 1H), 4.64 (s, 1H), 4.78 (ABd, JAB = 11.2 Hz, 1H), 5.16 (t, J = 9.7 Hz, 1H), 5.44 (d, J = 8.1 
Hz, 1H), 5.78 (dd, J = 10.6 and 9.2 Hz, 1H), 7.21-7.38 (m, 10H), 7.71-7.74 (m, 2H), 7.82-7.84 (m, 2H); 
MS FAB(+) m/z 914 [(M+Na)
+
, 62]; HRMS calcd for C46H57O15NSiNa [(M+Na)
+





A mixture of 24 (1.14 g, 1.28 mmol) and acetic anhydride (5 mL) in pyridine (5 mL) was stirred at 
room temperature for 2 h and methanol (20 mL) was added. The solvent was removed, and the residue 
was purified by silica gel chromatography (hexane : ethyl acetate = 2 : 1) to give 25 (1.18 g, 99%). 
1
H-
NMR (300 MHz, CDCl3) δ: -0.19 (s, 3H), -0.18 (s, 3H), 0.77 (s, 9H), 1.85 (s, 3H), 1.95 (s, 3H), 2.01 (s, 
6H), 3.22 (d of ABd, JAB = 11.3 Hz, J = 7.2 Hz, 1H), 3.40 (d of ABd, JAB = 11.3 Hz, J = 2.6 Hz, 1H), 
 20 
3.55-3.62 (m, 1H), 3.75-3.81 (m, 2H), 4.11-4.24 (m, 3H), 4.32 (ABd, JAB = 11.6 Hz, 1H), 4.44 (ABd, 
JAB = 11.7 Hz, 1H), 4.44 (dd, J = 10.8 and 8.6 Hz, 1H), 4.60 (ABd, JAB = 11.6 Hz, 1H), 4.69 (d, J = 2.4 
Hz, 1H), 4.70 (ABd, JAB = 11.7 Hz, 1H), 4.88 (t, J = 9.1 Hz, 1H), 5.15 (t, J = 9.5 Hz, 1H), 5.53 (d, J = 
8.4 Hz, 1H), 5.74 (dd, J = 10.7 and 9.1 Hz, 1H), 7.22-7.35 (m, 10H), 7.68-7.71 (m, 2H), 7.80-7.83 (m, 
2H); MS FAB(+) m/z 956 [(M+Na)
+






glucopyranosyl]-α-D-mannopyranoside (26).  
A mixture of 25 (1.17 g, 1.25 mmol), pyridinium p-toluenesulfonate (32 mg, 0.13 mmol), and 
methanol (10 mL) was stirred at 50 ºC for 2 h. The solvent was removed, and the residue was purified 
by silica gel chromatography (hexane : ethyl acetate = 1 : 1) to afford 26 (765 mg, 75%). 
1
H-NMR (300 
MHz, CDCl3) δ: 1.44 (br.dd, J = 9.4 and 4.4 Hz, 1H), 1.88(s, 3H), 1.95 (s, 3H), 2.03 (s, 3H), 2.04 (s, 
3H), 3.03-3.10 (m, 1H), 3.17-3.25 (m, 1H), 3.39-3.46 (m, 1H), 3.80-3.84 (m, 2H), 4.10-4.11 (m, 1H), 
4.16-4.21 (m, 1H), 4.22-4.28 (m, 1H), 4.35 (ABd, JAB = 11.7 Hz, 1H), 4.42-4.48 (m, 1H), 4.47 (ABd, 
JAB = 11.9 Hz, 1H), 4.51 (ABd, JAB = 11.7 Hz, 1H), 4.68 (ABd, JAB = 11.9 Hz, 1H), 4.71 (d, J = 2.0 Hz, 
1H), 4.93 (t, J = 9.6 Hz, 1H), 5.17 (t, J = 9.6 Hz, 1H), 5.45 (d, J = 8.4 Hz, 1H), 5.82 (dd, J = 10.7 and 
9.1 Hz, 1H), 7.17-7.21 (m, 2H), 7.26-7.35 (m, 8H), 7.71-7.74 (m, 2H), 7.83-7.86 (m, 2H); MS FAB(+) 
m/z 842 [(M+Na)
+
, 100]; HRMS calcd for C42H45O16NNa [(M+Na)
+
] 842.2636, found: 842.2639. 
 
4.1.22. Benzyl 2,6-di-O-[3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-ß-D-glucopyranosyl]-4-O-acetyl-
3-O-benzyl-α-D-mannopyranoside (27).  
To a mixture of 26 (564 mg, 0.69 mmol), silver trifluoromethanesulfonate (318 mg, 1.24 mmol), and 
collidine (164 µL, 1.24 mmol) in nitromethane (5 mL) was added a nitromethane (5 mL) solution of 6 
(514 mg, 1.03 mmol) at –20 ºC. The reaction mixture was stirred at –20 ºC for 30 min and room 
temperature for 2 h before being filtered through Celite
®
 and concentrated in vacuo. The residue was 
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purified by silica gel chromatography (1st; hexane : ethyl acetate = 1 : 1, 2nd; chloroform : methanol = 
20 : 1) to afford 27 (337 mg, 40%). 
1
H-NMR (300 MHz, CDCl3) δ: 1.83, 1.86, 1.91, 2.00, 2.01, 2.03 and 
2.07 (each s, 3H), 2.87-2.94 (m, 1H), 3.55-3.74 (m, 6H), 4.00-4.01 (m, 1H), 4.07-4.41 (m, 7H), 4.35 
(ABd, JAB = 12.0 Hz, 1H), 4.47 (d, J = 2.0 Hz, 1H), 4.59 (ABd, JAB = 12.0 Hz, 1H), 4.73 (t, J = 9.4 Hz, 
1H), 5.00 (d, J = 8.3 Hz, 1H), 5.06 (t, J = 9.4 Hz, 1H), 5.12 (t, J = 9.4 Hz, 1H), 5.42 (d, J = 8.6 Hz, 1H), 
5.71 (dd, J = 10.7 and 9.1 Hz, 1H), 7.01-7.04 (m, 2H), 7.18-7.29 (m, 8H), 7.61-7.76 (m, 6H), 7.83-7.86 
(m, 2H); MS FAB(+) m/z 1259 [(M+Na)
+






O-benzyl-α-D-mannopyranoside (28).  
To an ethanol (10 mL) solution of 27 (157 mg, 0.13 mmol) was added hydrazine·hydrate (80% in 
water, 200 µL). The reaction mixture was heated at reflux for 4 h before being concentrated in vacuo. 
The residue was dissolved in pyridine (2 mL) and acetic anhydride (2 mL) was added. The mixture was 
stirred overnight at room temperature and methanol (20 mL) was added. The solvent was removed, and 
the residue was purified by silica gel chromatography (chloroform : methanol = 20 : 1) to give 28 (125 
mg, 93%, 2 steps). 
1
H-NMR (300 MHz, CDCl3) δ: 1.94, 1.98, 2.02, 2.02, 2.04 and 2.06 (each s, 3H), 
2.07 (s, 6H), 2.07 (s, 3H), 2.98 (br dt, J = 7.1 and 9.5 Hz, 1H), 3.13 (br d, J = 10.6 Hz, 1H), 3.56 (br d, J 
= 9.8 Hz, 1H), 3.64 (ddd, J = 2.6, 4.7 and 9.5 Hz, 1H), 3.79 (br dt, J = 3.0 and 10.1 Hz, 1H), 3.87 (dd, J 
= 3.7 and 9.8 Hz, 1H), 4.09-4.15 (m, 5H), 4.21-4.32 (m, 4H), 4.51 (ABd, JAB = 11.8 Hz, 1H), 4.65 (ABd, 
JAB = 11.8 Hz, 1H), 4.73 (d, J = 11.4 Hz, 1H), 4.96 (t, J = 9.2 Hz, 1H), 5.00 (t, J = 9.3 Hz,1H), 5.03-5.11 
(m, 2H), 5.30 (t, J = 9.8 Hz, 1H), 5.54 (d, J = 8.4 Hz, 1H), 5.98 (dd, J = 9.2 and 10.7 Hz, 1H), 6.63 (d, J 
= 9.8 Hz, 1H), 7.24-7.39 (m, 11H); MS FAB(+) m/z 1061 [(M+H)
+
, 5]; HRMS calcd for 
C50H65N2O23Na [(M+H)
+





To an ethanol (10 mL) solution of 28 (118 mg, 0.11 mmol) was added Pd-C (10%, ca. 100 mg) and 
ammonium formate (140 mg). The reaction mixture was refluxed overnight, filtered through Celite
®
 and 
concentrated in vacuo. The residue was dissolved in pyridine (2 mL) and acetic anhydride (2 mL) was 
added. The mixture was stirred overnight at room temperature and methanol (20 mL) was added. The 
solvent was removed, and the residue was purified by silica gel chromatography (chloroform : methanol 
= 20 : 1) to give 29 (78 mg, 72%, 2 steps). 
1
H-NMR (300 MHz, CDCl3) δ: 1.97, 2.00, 2.01, 2.02, 2.05, 
2.06, 2.06, 2.09, 2.11 and 2.12 (each s, 3H), 2.97-3.05 (m, 2H), 3.13-3.16 (m, 1H), 3.62-3.66 (m, 1H), 
3.75-3.79 (m, 2H), 3.96-4.01 (m, 1H), 4.10-4.29 (m, 6H), 4.92 (t, J = 9.7 Hz, 1H), 5.06-5.10 (m, 4H), 
5.45 (t, J = 9.7 Hz, 1H), 5.46 (d, J = 9.2 Hz, 1H), 5.90 (dd, J = 10.6 and 9.2 Hz, 1H, 6.05 (d, J = 1.8 Hz, 
1H), 6.41 (d, J = 9.5 Hz, 1H), 7.23 (d, J = 3.9 Hz, 1H); MS FAB(+) m/z 965 [(M+H)
+
, 5]; HRMS calcd 
for C40H57N2O25 [(M+H)
+
] 965.3250, found: 965.3255. 
 
4.1.25. 2-(4-Iodophenyl)ethyl 6-O-[2,6-di-O-(3,4,6-tri-O-acetyl-2-acetamido-2-deoxy-ß-D-
glucopyranosyl)-3,4-di-O-acetyl-α-D-mannopyranosyl]-2,3,4-tri-O-acetyl-ß-D-glucopyranoside (31).  
To a solution of 29 (70 mg, 0.073 mmol) and acetic anhydride (1.5 mL) was added hydrogen bromide 
(30% in acetic acid, 3 mL). The mixture was stirred overnight at room temperature, poured into ice 
water, and extracted with chloroform. The organic layer was washed with water and a saturated sodium 
hydrogencarbonate solution, dried over sodium sulfate, filtered, and evaporated to give 30 (67 mg). To a 
solution of 4 (30 mg, 0.055 mmol), dichloromethane (1 mL), and toluene (1 mL) was added silver 
carbonate (17 mg, 0.06 mmol). The reaction mixture was stirred at room temperature for 1 h under a 
nitrogen atmosphere, and silver perchlorate (2 mg, 0.0082 mmol) was added. After stirring for 30 min at 
room temperature, a solution of 30 (65 mg, 0.066 mmol), dichloromethane (2 mL), and toluene (2 mL) 
was added and the mixture was stirred for another 15 h. After the reaction was completed, the mixture 
was filtered. The filtrate was concentrated in vacuo, and the residue was purified by silica gel 
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chromatography (chloroform : methanol = 20 : 1) to afford 31 (5 mg, 7%, 2 steps). 
1
H-NMR (400 MHz, 
CDCl3) δ: 1.87, 1.94, 1.96, 1.97, 1.99, 2.00, 2.03, 2.04, 2.05, 2.06, 2.08, 2.09, and 2.09 (each s, 3H), 
2.82-2.96 (m, 3H), 3.06-3.09 (m, 1H), 3.55-3.58 (m, 1H), 3.63-3.73 (m, 5H), 3.77-3.82 (m, 1H), 3.98-
4.01 (m, 1H), 4.09-4.32 (m, 8H), 4.45 (d, J = 8.1 Hz, 1H), 4.82 (d, J = 1.5 Hz, 1H), 4.88-4.98 (m, 3H), 
5.02-5.10 (m, 3H), 5.17 (t, J = 9.5 Hz, 1H), 5.35 (t, J = 9.6 Hz, 1H), 5.38 (d, J = 8.2 Hz, 1H), 5.92 (dd, J 
= 10.8 and 9.2 Hz, 1H), 6.43 (d, J = 9.9 Hz, 1H), 6.95-6.97 (m, 2H), 7.30 (d, J = 7.0 Hz, 1H), 7.56-7.59 
(m, 2H); MS FAB(+) m/z 1463 [(M+Na)
+






mannopyranosyl]-ß-D-glucopyranoside (IPGGMG, 2).  
To a methanol (1 mL) solution of 31 (13 mg, 0.009 mmol) was added sodium methoxide (28% in 
methanol, 10 µL, 0.050 mmol) and the mixture was stirred at room temperature for 30 min. After the 
reaction was completed, the mixture was neutralized with Amberlyst
®
 15 (ca. 100 mg) and filtered. The 
filtrate was concentrated in vacuo to afford 2 (5 mg, 57%). 
1
H-NMR (400 MHz, CD3OD) δ: 2.02, 2.06 
(each s, 3H), 2.85-2.93 (m, 2H), 3.12-3.19 (m, 1H), 3.24-3.38 (m, 8H), 3.45-3.76 (m, 11H), 3.84-3.89 
(m, 3H), 3.96 (br s, 1H), 4.01-4.10 (m, 2H), 4.28 (d, J = 7.7 Hz, 1H), 4.45 (d, J = 8.2 Hz, 1H), 4.58 (d, J 
= 7.7 Hz, 1H), 4.80 (s, 1H), 7.06-7.09 (m, 2H), 7.59-7.61 (m, 2H); MS FAB(+) m/z 1001 [(M+Na)
+
, 2]; 
HRMS calcd for C36H55O21N2INa [(M+Na)
+
] 1001.2240, found: 1001.2245. 
 
4.2. Iododestannylation Reaction. 
The radiolabeled compound [
125
I]20 was prepared from the corresponding tributyltin derivative 21 by 
iododestannylation. Briefly, to initiate the reaction, 10 µL of H2O2 (5%) was added to a mixture of a 
tributyltin derivative (100 µg/100 µL MeOH), 0.2 mCi sodium [
125
I]iodide, and 20 µL of 0.1N HCl in a 
sealed vial. The reaction was allowed to proceed at room temperature for 30 min. The reaction mixture 
was neutralized with sodium bicarbonate, and extracted with ethyl acetate. The extract was evaporated 
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and methanol (100 µL) was added. To the solution was added sodium methoxide (28% in methanol, 1.6 
µL). The reaction mixture was stirred at room temperature for 45 min, and neutralized with Amberlyst
®
 
15. The residue was purified by HPLC on a Cosmosil 5C18 AR-300 column (4.6×150 mm) with an 
isocratic solvent of H2O/acetonitrile (83/17) at a flow rate of 1.0 mL/min. 
 
4.3. Enzymatic Reactions of Radioiodinated IPGMG. 
GnT-V-transfected WiDr cells were used as the enzyme source. The protein concentration was 
measured by the Lowry method.
23
 Lysate of GnT-V-overexpressing WiDr cells was incubated with 
MES buffer (125 mM, pH 6.25) containing 40 mM UDP-GlcNAc, 200 mM GlcNAc, 0.5% Triton X-
100, and 10 mM EDTA for 10 min at 37°C. [
125
I]IPGMG was then added, and the incubation continued 
for an additional 4 h. The reaction was stopped by heating at 100°C for 1 min. Enzymatic products were 
analyzed by HPLC on a TSK-GEL ODS-80TM column (4.6×150 mm) with an isocratic solvent of 
H2O/acetonitrile (85/15) at a flow rate of 1.0 mL/min. 
 
4.4. GnT-V Activities in Rat Tissues. 
Animal experiments were conducted in accordance with our institutional guidelines, and the 
experimental procedures were approved by the Kyoto University Animal Care Committee. Various 
tissues from male Wistar rats weighing 240-260 g were homogenized in 4 volumes of 10 mM Tris-HCl 
buffer (pH 7.4) containing 0.25 M sucrose. After centrifugation at 900 × g for 10 min, the supernatants 
were collected and used as crude enzyme preparations. The GnT-V activity and protein concentration 
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Figure 1. Glycosylation of [
125
I]1 by GnT-V. 
Figure 2. Chromatogram of reaction products of [
125
I]1. 
Figure 3. (A) Michaelis–Menten’s curve of the GnT-V-catalyzed reaction: (B) Lineweaver–Burk plot 
of the GnT-V-catalyzed reaction. 
 
 
SCHEME LEGENDS  
Scheme 1. Synthesis of trisaccharide 1. 
Scheme 2. Synthesis of disaccharide 3. 
Scheme 3. Synthesis of glucose derivative 4. 
Scheme 4. Synthesis of 1 and [
125
I]1. 
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a: AgOTf, collidine, CH3NO2, b:  NH2NH2
. H2O, EtOH, c: Ac2O, pyridine, d: 70% AcOH, e: 10% Pd-C, H2, EtOH, 
f: 30% HBr-AcOH.




  80 % 
(2 steps)
e, c





































18: X=I  (94 %)
19: X=SnBu3 (95 %)




a: AllocCl, pyridine, THF, b: piperidine, THF, c: CCl3CN, DBU, CH2Cl2, d: 2-(4-bromophenyl)ethyl alcohol, BF3
. Et2O, 
CH2Cl2, e: Pd(PPh3)4, PPh3, HCO2H, THF, f: ethyl vinyl ether, PPTS, CH2Cl2, g: Pd(PPh3)4, PPh3, (n-Bu3Sn)2, DMF, h: I2, 


















































+   4 or 19
21: X=SnBu3, R = Ac (43 %)
20: X=I, R = Ac (67 %)
22: X=SnBu3, R =H
  1: X=I, R =H (59 %)
b (for 19)
a (for 4)
a: AgClO4, Ag2CO3, CH2Cl2, toluene, b: AgClO4, collidine, CH2Cl2, toluene, c: NaOMe, MeOH,
d: [125I]NaI, 5 % H2O2 aq., 0.1 % HCl aq.
c
[125I]20: X=125I, R = Ac
d c
[125I]1: X=I, R =H
 






























































28: R = Bn
31: R = Ac
  2: R = H
a e
f, c  i
j
a: 70% AcOH, b: TBSCl, imidazole, DMF, c: Ac2O, pyridine, d: PPTS, CH2Cl2, e: 6, AgOTf, collidine, CH3NO2, f: NH2NH2
. 
H2O, EtOH, g: 10% Pd-C, H2, EtOH, h: 30% HBr-AcOH, Ac2O, i: 4, AgClO4, Ag2CO3, CH2Cl2, toluene, j: NaOMe, MeOH.
83 % 40 %
  93 %
(2 steps)
   7 %
(2 steps)
24: R1 =TBS,  R2 = H (94%)
25: R1 =TBS,  R2 = Ac (99%)




29: R = Ac (72%, 2 steps)
g, c
h
30: R = Br
 
Scheme 5.  
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TABLES. 
Table 1. GnT-V activity in rat tissues determined with [
125
I]1 or Gn,Gn-bi-PA 
as a substrate. 
 
tissue 








Heart 31 ± 1 10 ± 1 
Liver 48 ± 5 8.2 ± 0.8 
Stomach 116 ± 65 25 ± 1 
Lung 179 ± 6 38 ± 4 
Spleen 244 ± 117 21 ± 2 
Brain 261 ± 18 38 ± 1 
Kidney 671 ± 240 30 ± 6 
Intestine 774 ± 67 68 ± 11 
Serum 1284 ± 223 112 ± 53 
a
 Each value represents the mean ± s.d. for three samples. 
b
 Results 
were reported previously.
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